WCM
TBPH icon

Wedge Capital Management’s Theravance Biopharma TBPH Stock Holding History

Wedge Capital Management’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.19M Buy
+128,845
New +$2.13M 0.04% 322

Other funds holding TBPH

MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
ICM
Irenic Capital Management New York $2.08B AUM 19.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Wedge Capital Management's TBPH Position: Q2 2026 in Review

Wedge Capital Management opened a new position in Theravance Biopharma (TBPH) in Q2 2026: 128,845 shares worth $2.19M. The stake represents 0.04% of the portfolio and ranks #322 among its holdings.

181 funds tracked by Wall St. Rank hold TBPH as of Q2 2026.

  • Wedge Capital Management held 128,845 shares of Theravance Biopharma worth $2.19M as of Q2 2026.
  • Theravance Biopharma was a new Wedge Capital Management position in Q2 2026.
  • Theravance Biopharma made up 0.04% of Wedge Capital Management's portfolio in Q2 2026, its #322 holding.
  • 181 funds tracked by Wall St. Rank held Theravance Biopharma as of Q2 2026.

Based on Wedge Capital Management's 13F filing for Q2 2026, filed 10 Jul 2026.